AI FOR SCIENCE · ON THE RECORD
Flagship Pioneering
Investor page →On the timeline →People filter →
Recent timeline
- 2026-10-29Flagship merges the platforms of Cellarity, Etiome and Empress Therapeutics into Etcelera, an AI drug discovery company led by Adrian RawcliffeOrganizations
- 2026-02-26Generate:Biomedicines prices a $400M Nasdaq IPOCapital
- 2025-03-10Lila Sciences emerges with $200 million for AI science factoriesCapital
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
Adrian RawcliffeCEO-Partner Flagship merges the platforms of Cellarity, Etiome and Empress Therapeutics into Etcelera, an AI drug discovery company led by Adrian Rawcliffe
Alec ReynoldsSenior Partner Flagship merges the platforms of Cellarity, Etiome and Empress Therapeutics into Etcelera, an AI drug discovery company led by Adrian Rawcliffe
Noubar AfeyanFounder and CEO Flagship merges the platforms of Cellarity, Etiome and Empress Therapeutics into Etcelera, an AI drug discovery company led by Adrian Rawcliffe
Geoffrey von MaltzahnGeneral Partner Lila Sciences · Series B · about $2 billion (in talks)- MMolly GibsonOrigination Partner Lila Sciences · Series B · about $2 billion (in talks)
Rounds it backed
- 2025-09-15Lila Sciences · Series A · $235Mparticipant
- 2025-03-10Lila Sciences · Seed · $200Mparticipant
- 2023-09-14Generate:Biomedicines · Series C · $273Mparticipant
- 2021-11-18Generate:Biomedicines · Series B · $370Mparticipant
Rounds on the funding record that name it as an investor, in the role each source gives. Its own rounds are not on the funding board, which covers AI4S startups; the timeline records them as events.
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.